TP53 Mutations in Korean Patients with Non-small Cell Lung Cancer.
10.3346/jkms.2010.25.5.698
- Author:
Eung Bae LEE
1
;
Guang JIN
;
Shin Yup LEE
;
Ji Young PARK
;
Min Jung KIM
;
Jin Eun CHOI
;
Hyo Sung JEON
;
Seung Ick CHA
;
Sukki CHO
;
Chang Ho KIM
;
Tae In PARK
;
Tae Hoon JUNG
;
Ji Woong SON
;
Jae Yong PARK
Author Information
1. Department of Thoracic Surgery, School of Medicine, Kyungpook National University, Daegu, Korea.
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Lung Neoplasms;
Mutation;
Genes, p53
- MeSH:
Carcinoma, Non-Small-Cell Lung/*epidemiology/*genetics;
Female;
Genetic Predisposition to Disease/*epidemiology/*genetics;
Humans;
Incidence;
Korea/epidemiology;
Lung Neoplasms/*epidemiology/*genetics;
Male;
Middle Aged;
Polymorphism, Single Nucleotide/genetics;
Risk Assessment/methods;
Risk Factors;
Tumor Suppressor Protein p53/*genetics
- From:Journal of Korean Medical Science
2010;25(5):698-705
- CountryRepublic of Korea
- Language:English
-
Abstract:
Although TP53 mutations have been widely studied in lung cancer, the majority of studies have focused on exons 5-8 of the gene. In addition, TP53 mutations in Korean patients with lung cancers have not been investigated. We searched for mutations in the entire coding exons, including splice sites of the gene, in Korean patients with non-small cell lung cancer (NSCLC). Mutations of the gene were determined by direct sequencing in 176 NSCLCs. Sixty-nine mutations (62 different mutations) were identified in 65 tumors. Of the 62 mutations, 12 were novel mutations. TP53 mutations were more frequent in males, ever-smokers and squamous cell carcinomas than in females, never-smokers and adenocarcinomas, respectively (all comparisons, P<0.001). Missense mutations were most common (52.2%), but frameshift, nonsense, and splice-site mutations were frequently observed at frequencies of 18.8%, 15.9% and 10.1%, respectively. Of the 69 mutations, 9 (13.0%) were found in the oligomerization domain. In addition, the proportion of mutations in the oligomerization domain was significantly higher in adenocarcinomas than in squamous cell carcinomas (23.5% vs. 2.9%, P=0.01). Our study provides clinical and molecular characteristics of TP53 mutations in Korean patients with NSCLCs.
